MetaVia shows uric acid reduction with DA-1726 in Phase 1
MetaVia announced that its interim Part 3B data from its 16-week, randomized, placebo-controlled Phase 1 study demonstrated a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid at Day 109 (p<0.001) following once-weekly DA-1726 in otherwise healthy adults with obe
<p>MetaVia announced that its interim Part 3B data from its 16-week, randomized, placebo-controlled Phase 1 study demonstrated a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid at Day 109 (p<0.001) following once-weekly DA-1726 in otherwise healthy adults with obe</p>